Welcome to our dedicated page for MAIA Biotechnology news (Ticker: MAIA), a resource for investors and traders seeking the latest updates and insights on MAIA Biotechnology stock.
MAIA Biotechnology, Inc. (NYSE American: MAIA) is a clinical-stage biopharmaceutical company whose news flow is closely tied to the development of ateganosine (THIO), a first-in-class telomere-targeting therapy for advanced non-small cell lung cancer (NSCLC). News about MAIA often centers on clinical milestones, regulatory designations, and financing activities that support its oncology programs.
Investors and observers following MAIA’s news can expect regular updates on its Phase 2 THIO-101 and Phase 3 THIO-104 trials. These items include announcements of first patient dosing, expansion into new countries, enrollment progress, and presentations of trial-in-progress posters at major conferences such as the Society for Immunotherapy of Cancer (SITC), the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, and the European Society for Medical Oncology (ESMO) Congress.
MAIA’s press releases, many of which are furnished via Form 8-K filings, also highlight regulatory developments such as the U.S. FDA Fast Track designation for ateganosine in NSCLC and Orphan Drug Designations in additional tumor types. Another recurring theme in the company’s news is insider activity: open-market share purchases by the CEO and directors, and participation by board members in private placement financings, which the company frames as signals of confidence in the ateganosine platform.
On this news page, readers can review MAIA’s announcements related to clinical data signals, trial design details, international site activations, and capital raises that fund key study steps. For those tracking the progress of telomere-targeting approaches in oncology and the later-line NSCLC treatment landscape, MAIA’s news provides an ongoing record of how its investigational therapy is advancing through mid- to late-stage clinical development.
MAIA Biotechnology (NYSE American: MAIA) reported positive Phase 2 clinical trial results for ateganosine (THIO) in combination with cemiplimab for advanced non-small cell lung cancer (NSCLC) patients. The trial showed remarkable efficacy with 5.6 months median progression-free survival in third-line treatment (180 mg dose), more than double the standard of care of 2.5 months.
The study demonstrated an estimated median overall survival of 17.8 months, with confidence intervals showing a lower bound of 12.5 months (95% CI) and 10.8 months (99% CI). Two patients completed 33 treatment cycles, indicating ateganosine's potential for extended dosing. The company has initiated a Phase 2 expansion trial in July 2025 to further validate these promising results.
MAIA Biotechnology (NYSE American: MAIA) announced that its abstract on ateganosine (THIO) treatment for non-small cell lung cancer (NSCLC) has been selected for poster presentation at the 2025 IASLC World Conference on Lung Cancer in Barcelona.
The presentation will highlight promising data from the THIO-101 trial, showing a median overall survival of 17.8 months with a 95% confidence interval lower bound of 12.5 months. Notably, the FDA has recently granted Fast Track designation for ateganosine in NSCLC treatment, potentially expediting its regulatory process towards Accelerated Approval and Priority Review.
MAIA Biotechnology (NYSE American: MAIA) announced the publication of interim clinical data from its Phase 2 THIO-101 trial in the peer-reviewed journal Cells. The manuscript, focused on "Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy," was authored by researchers from Turkey and the U.S., including MAIA's scientific team.
The publication highlights MAIA's novel combination strategy using ateganosine sequenced with a checkpoint inhibitor, which has shown promising results in addressing the challenge of patient resistance to conventional immunotherapies. This development represents a potential breakthrough for patients with high unmet medical needs in non-small cell lung cancer treatment.
MAIA Biotechnology (NYSE American: MAIA) has been granted a European patent for its portfolio of ateganosine-based analogues targeting cancer therapy. The patent covers mercaptopurine ribonucleoside analogues that function as cancer-fighting immunosuppressive agents, disrupting telomere structure and reducing immune system activity to combat cancer cell growth.
The technology, invented by MAIA's CSO Dr. Sergei Gryaznov and Scientific Advisory Board member Dr. Jerry Shay, represents a significant advancement in telomere-targeting compounds with potentially improved cancer cell specificity. The company's global IP portfolio now includes 10 issued patents worldwide, with European validation in 19 countries, and 24 pending patent applications.
MAIA Biotechnology (NYSE American: MAIA) has received FDA Fast Track designation for ateganosine, its first-in-class small molecule treatment for non-small cell lung cancer (NSCLC). The drug, currently in a pivotal Phase 2 THIO-101 clinical trial, has shown promising results with a median overall survival of 17.8 months, significantly outperforming standard treatments that typically achieve 5-6 months survival.
Ateganosine targets telomere structure in cancer cells and works through telomerase-mediated action to reverse resistance to immune checkpoint inhibitors. The company is targeting a $34.1 billion NSCLC market that is projected to reach $68.8 billion by 2033. If successful, MAIA could receive accelerated FDA approval as early as next year.
MAIA Biotechnology (NYSE American: MAIA) announced the publication of preclinical data for its second-generation ateganosine prodrugs platform in Nucleic Acids Research journal. The study focuses on novel telomere-targeting dual-pharmacophore dinucleotide prodrugs for cancer treatment.
The company has developed over 80 ateganosine-like compounds and nominated two key candidates: MAIA-2021-20 (lead) and MAIA-2022-12 (backup). The research demonstrated that these compounds, when combined with immune checkpoint inhibitors, showed superior anticancer efficacy and stronger host immune-memory responses compared to monotherapies. MAIA plans to advance at least one candidate to human clinical trials following completion of required studies.
MAIA Biotechnology (NYSE American: MAIA) has announced the dosing of its first patient in Taiwan for the expansion phase of the THIO-101 Phase 2 trial, evaluating ateganosine in advanced non-small cell lung cancer (NSCLC). The trial focuses on heavily pre-treated third-line NSCLC patients who previously failed checkpoint inhibitors and chemotherapy treatments.
The study includes two treatment arms: ateganosine with cemiplimab (Libtayo®) and ateganosine monotherapy. Current data shows median overall survival of 17.8 months for third-line treatment patients, significantly exceeding the typical 5-6 months survival with chemotherapy. The NSCLC market, valued at $34.1B in 2024, is projected to reach $68.8B by 2033 with an 8.1% CAGR.
MAIA Biotechnology (NYSE American: MAIA) announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress in Istanbul, Turkey, scheduled for July 5-9, 2025. The presentations will focus on the company's telomere-targeting cancer therapeutics.
The first poster, presented by Dr. Z. Gunnur Dikmen, will discuss how RiboTHIO and THIO work synergistically with radiotherapy and immune checkpoint blockade in lung tumor treatment. The second poster, presented by Gamze Tuna, will explore the effects of novel telomerase-mediated compounds on DNA damage and repair in A549 cells.
The company also reported that its THIO-101 Phase 2 clinical trial for ateganosine in non-small cell lung cancer (NSCLC) demonstrated a median overall survival of 17.8 months in heavily pre-treated patients, based on May 15, 2025 data.
MAIA Biotechnology (NYSE American: MAIA) has strengthened its Scientific Advisory Board by appointing two leading HCC specialists, Dr. Claudia Fulgenzi and Dr. David J. Pinato. The appointments come as MAIA prepares for a Phase 2 clinical trial of its lead candidate ateganosine (THIO) in hepatocellular carcinoma (HCC).
The company expects to begin patient enrollment in the HCC trial by year-end, leveraging its 2022 FDA Orphan Drug Designation for ateganosine in HCC treatment, which could provide up to seven years of market exclusivity. Both appointees bring extensive expertise in liver cancer research and immunotherapy, with Dr. Pinato serving as Director of Developmental Cancer Therapeutics at Imperial College London and Dr. Fulgenzi specializing in immune-oncology at Imperial College London.